Specialty Pharmacy

Einodshofer explains how the costs associated with one specialty patient's treatment can have the same financial footprint as an entire population of patients. Video from PBMI's Drug Benefit Conference 2013.

A bill passed by the Florida legislature would allow pharmacists to substitute biosimilars for brand-named biologics provided that a number of criteria are met.

The value of a specialty therapy lies not only in its clinical safety and efficacy, but also in how its price compares with other therapies in its class, found a new report.

United States spending on specialty prescription drugs is projected to increase 67% by the end of 2015, according to a forecast released today by Express Scripts.

The National Association of Specialty Pharmacy (NASP) announced it will host its 2013 Fall Strategic Business Exchange meeting on October 14-16, 2013 in San Antonio.

Specialty drugs drove spend in 2012 and accounted for almost two-thirds of spending on branded products.

The FDA approved the first companion diagnostic to detect epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10% of non-small cell lung cancers.

David Hileman, senior vice president of Omnicare, recently discussed how market access to oncology medications is changing and presented strategies manufacturers can use to support patient need through compliant distribution channels.

The Specialty Pharmacy Association of America (SPAARx), the largest national association representing the broad interests of the specialty pharmacy industry, celebrated its official launch at the 2013 Annual Armada Specialty Pharmacy Summit in Las Vegas, NV, on May 8, 2013

Representatives from the pharmaceutical industry and the managed care arena recently squared off at the 2013 Armada Specialty Pharmacy Summit about the costs and benefits of copay offset programs for biologics.

Specialty Pharmacy Times interviewed Andrew Pollack of The New York Times to find out how a top biotechnology journalist covers developments in the pharmaceutical pipeline accurately and succinctly, all while keeping the interest of the reader.

A new payer study from Avalere Health LLC and Janssen Biotech, Inc released at the 2013 Armada Specialty Pharmacy Summit seeks to determine which innovative strategies will be most successful in managing access to specialty drugs.

The Specialty Pharmacy Certification Board recently announced that it has approved the exam content outline for the Certified Specialty Pharmacist (CSP) certification examination.

In this video, executives from AstraZeneca and MedImmune explain why access to innovation in the development of biologics is so important.

We discussed the highlights of Express Scripts' Workers' Compensation Report with Rochelle Henderson, director of health services research, research and new solutions, to learn more about how employees use prescription drugs through workers' compensation.

The 2.1% increase in total prescription drug costs in 2012 was driven by a 19.1% increase in specialty drug costs.

During CVS Caremark's first quarter earnings conference call on May 1, 2013, executives revealed that specialty is and will continue to be a "top priority."

Patrick Gleason, PharmD, BCPS, FCCP, director of Health Outcomes at Prime Therapeutics, discusses the value of pharmacogenomic testing and the factors that influence whether a health plan or PBM will reimburse for the use of that test.

EvaluatePharma's first-ever report covering the orphan disease sector predicted that the orphan drug market will reach $127 billion by 2018 and will grow at a rate that is nearly twice that of the overall prescription drug market.

The FDA today approved Procysbi (cysteamine bitartrate) for the management of nephropathic cystinosis in children and adults.

The Academy of Managed Care Pharmacy recently informed legislators in Oregon and California of its opposition to biosimilar substitution laws pending concrete FDA guidance.

A new report from Fitch Ratings identifies the most promising business development tactics and targets for 3 small market players in the specialty pharmaceutical space.

The FDA's restricted distribution programs, intended for medications with toxicity risks or other potential dangers, may also be used to impede biosimilar competition, according to a Federal Trade Commission amicus brief filed in the US District Court for the District of New Jersey.

JAK therapies and their origins were discussed in an educational session at the 17th Annual International Congress on Hematologic Malignancies on February 15-17, 2013, in NYC.

Patrick Gleason, PharmD, BCPS, FCCP, director of health outcomes for Prime Therapeutics, explains how split-fill programs can help reduce waste for expensive specialty medications.

Armada Health Care announced today that the AIDS Healthcare Foundation (AHF) has chosen Armada to be its primary purchasing partner.

Roper Industries, Inc announced that it has entered into a definitive agreement to acquire Managed Health Care Associates, Inc (MHA) in a cash transaction valued at $1.0 billion.